The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis.
- Author:
Sang Beom KIM
1
;
Kyung Hyun RYOO
;
Kyeong Woo LEE
;
Hyun KWAK
;
Kisung YOON
Author Information
1. Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Korea. ryukh74@nate.com
- Publication Type:Original Article
- Keywords:
Vitamin K2;
Risedronate;
Postmenopausal osteoporosis;
Bone metabolism
- MeSH:
Bone Density;
Calcium Citrate;
Female;
Femur;
Humans;
Metabolism;
Osteocalcin;
Osteoporosis, Postmenopausal*;
Risedronate Sodium;
Spine;
Vitamin D;
Vitamin K 2*;
Vitamins*
- From:Journal of the Korean Academy of Rehabilitation Medicine
2006;30(5):491-495
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosis METHOD: We enrolled 21 postmenopausal osteoporosis women (age: 65.2+/-7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7+/-1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment. RESULTS: After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups. CONCLUSION: There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis.
